Locations:
Min Investment:
Max Investment:
Target Investment:
Total Funding: $100M
Total Funding: $290M
Total Funding: $250M
Total Funding: $160M
Total Funding: $190M
Total Funding: $110M
Total Funding: $150M
Total Funding: $56M
Total Funding: $160M
Total Funding: $140M
Total Funding: $57M
Total Funding: $51M
Total Funding: $100M
Total Funding: $140M
Total Funding: $87M
Total Funding: $32M
Total Funding: $130M
Total Funding: $64M
2000
2000
James Healy, M.D., PhD. Medical scientist, proven investor and value-added board member with 20+ years’ experience funding tomorrow’s cures. Dr. Healy finances companies in the US and Europe that are developing innovative therapies that can be transformative for patients. At Sofinnova he has funded twelve products that were approved by the FDA or EMA. Twenty-one of his investments have gone public and eleven have been acquired as private or public companies. Jim received a B.A. in Molecular Biology and B.A. Scandinavian Studies from UC Berkeley where he graduated with Honors and received the Departmental Citation. He subsequently completed the Medical Scientist Training Program and received his MD and PhD in Immunology from Stanford University where he was a Beckman Scholar and received the Novartis Foundation Bursary Award. He authored or co-authored thirteen scientific articles and reviews, including three papers published in Nature. He has lectured on entrepreneurship at Stanford University and served on the boards of the Executive Committee at UC Berkeley, the Biotechnology Industry Organization (BIO) and the National Venture Capital Association (NVCA). Previous investments include Amarin (AMRN), Appelis (APLS), Audentes (BOLD), Cellective, Cotherix (CTRX), Durata (DRTX), Hyperion (HYPN), InterMune (ITMN), Movetis (MOVE), Nextwave, Novacea (NOVA), Preglem, Prestwick, Salveo and Tesaro (TSRO). He currently sits on the board of directors of Ascendis (ASND), Coherus (CHRS), Iterum (ITRM), Natera (NTRA), Nucana (NCNA), Obseva (OBSV) and Y-Mabs (YMAB).
2019
2021
2019
2018
2018
2014
2014
2014
2014
2014
2017
2017
2014
Lead Investor